ABSTRACT
Placenta increta, a rare complication of pregnancy, is associated with significant postpartum hemorrhage often requiring emergency hysterectomy. We report a case of conservative management, with a combination of parenteral methotrexate, serial ultrasound and Doppler assessment, followed by interval manual removal of placenta.
Subject(s)
Antibiotic Prophylaxis , Placenta Accreta/drug therapy , Adult , Anti-Bacterial Agents/therapeutic use , Autolysis , Cefuroxime/therapeutic use , Female , Humans , Postpartum Period , Pregnancy , Treatment Outcome , Uterus/drug effectsABSTRACT
The term 'fetal distress' should be replaced by 'suspected fetal compromise' because the diagnosis of 'fetal distress' is often unproven. Cardiotocography remains the cornerstone of making the diagnosis, but as a test it is renowned for its high sensitivity and low specificity. It has reduced intrapartum fetal mortality but not long-term neonatal morbidity or the incidence of cerebral palsy. There is no doubt that when obvious signs of fetal compromise, such as late decelerations in the presence of intrauterine growth retardation and oligohydramnios, are present, the diagnosis of fetal compromise is relatively simple. Often, however, the subtle signs of fetal compromise are missed; these are a change in the grade of meconium in the amniotic fluid, a rising base-line fetal heart rate, the absence of accelerations, the presence of 'atypical' variable decelerations or a combination of the above. To date, there is no test available to replace the cardiotocograph, although fetal pulse oximetry is the most promising adjunctive test. Above all, no test result obtained in isolation must detract from the whole clinical picture.
Subject(s)
Fetal Distress/diagnosis , Fetal Monitoring/methods , Heart Rate, Fetal/physiology , Biomarkers/blood , Cardiotocography/methods , Female , Fetal Blood , Fetal Distress/blood , Fetal Monitoring/instrumentation , Humans , Meconium , PregnancyABSTRACT
In mid-trimester amniocentesis (MTA), 12-15 ml of amniotic fluid is aspirated for cytogenetic analysis. When a similar volume of amniotic fluid is removed by early amniocentesis (EA), it represents a significant proportion of the total amniotic fluid volume in the first trimester. The fluid depletion, which may persist for 7 to 10 days, is considered to impair development of fetal lungs and extremities and, possibly, contribute towards procedure-related congenital abnormalities and miscarriages. By only removing 7 ml of amniotic fluid, we have demonstrated a total miscarriage rate (3.8 per cent) comparable with previous large studies (Table V), a low incidence of respiratory difficulties at birth (2.7 per cent) and a low incidence of fixed flexion deformities (1.6 per cent), at the expense of a small increase in the incidence of culture failure (2.2 per cent).
Subject(s)
Amniocentesis/adverse effects , Amniotic Fluid , Gestational Age , Pregnancy Outcome , Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/etiology , Adult , Chromosome Aberrations , Congenital Abnormalities/epidemiology , Congenital Abnormalities/etiology , Female , Fetal Organ Maturity , Humans , Infant, Newborn , Lung/embryology , PregnancyABSTRACT
The effect on pregnancy outcome of transplacental needle insertion was studied in 401 consecutive women attending for early amniocentesis between 10 and 14 completed weeks of pregnancy. Transplacental early amniocentesis was associated with a significantly higher incidence (P < 0.001) of blood-stained amniotic fluid taps but a lower incidence (not significant; P > 0.05) of pregnancy loss and miscarriages. Women in the nontransplacental early amniocentesis group had a significantly higher (P < 0.01) incidence of late procedure-related antenatal complications, such as preterm rupture of membranes or preterm labour. Our study showed that transplacental early amniocentesis is a safe procedure; contrary to present recommendations, the study also showed that avoiding the placenta during early amniocentesis is an unnecessary practice.
Subject(s)
Amniocentesis/methods , Pregnancy Outcome , Amniocentesis/adverse effects , Female , Humans , Pregnancy , Pregnancy Trimester, FirstABSTRACT
The concentrations of interleukin-1 alpha (IL-1 alpha) and IL-6 in pregnancy-associated tissues were investigated in term labour and delivery in the absence of labour (elective Caesarean section). Samples of amniotic fluid, placenta, fetal membranes, umbilical venous and, where possible, umbilical arterial blood were collected at delivery (37-41 weeks of gestation). Maternal blood was sampled during labour. Fluid and tissue extracts were assayed for IL-1 alpha and IL-6 by radioimmunoassay. Placenta and membranes were examined histologically for evidence of infection. Concentrations of IL-1 alpha and IL-6 in amniotic fluid and membrane extract, and IL-1 alpha in maternal and fetal blood, were raised after the onset of labour. Concentrations of both cytokines in the placenta remained unchanged. There was a good correlation between concentrations of both cytokines in amniotic fluid and membranes. There was also a significant correlation between concentrations of IL-1 alpha and IL-6 in amniotic fluid, placenta and membranes. It is suggested that the fetal membranes or maternal decidua, but not the placenta, internal fetal or maternal tissues, are the main sources of IL-1 alpha and IL-6 during labour.
Subject(s)
Interleukin-1/analysis , Interleukin-6/analysis , Pregnancy/metabolism , Amniotic Fluid/chemistry , Decidua/chemistry , Extraembryonic Membranes/chemistry , Female , Humans , Labor, Obstetric/metabolism , Placenta/chemistry , Umbilical Arteries , Umbilical VeinsABSTRACT
OBJECTIVE: To assess the effectiveness of laser endometrial ablation in women with dysfunctional bleeding. DESIGN: A retrospective analysis of 90 patients. SETTING: Department of Gynaecology, King George Hospital, Barley Lane, Goodmayes, Essex IG3 8YB, U:K. SUBJECTS: Ninety patients with dysfunctional uterine bleeding who were hysteroscopically suitable for laser endometrial ablation. INTERVENTIONS: Endometrial laser ablations using the neodynium-yttrium-garnet laser at 70 watts power output. MAIN OUTCOME MEASURES: Patient satisfaction/dissatisfaction at 6 months follow-up and response to repeat ablation. RESULTS: A total of 117 procedures were carried out on the 90 patients. There was one suspected perforation which was not confirmed at subsequent hysterectomy and one primary hemorrhage which required tamponade with Foley catheter. There were three cases of fluid overload with no clinical evidence of fluid over-load syndrome. All five major complications occurred in the first six months or 'learning phase' of the study. During this period, there were proportionately more treatment failures after one attempt (52.8% versus 42.6%) than the second six months of the study. Overall, 53.3% of the patients were satisfied with the initial ablation and 73.3% were satisfied after repeat ablations. CONCLUSION: Endometrial laser ablation is a major advance in the management of dysfunctional uterine bleeding, especially in patients who would otherwise have had a hysterectomy.